Home » Newsletters » BioWorld Science

BioWorld Science

March 28, 2006

View Archived Issues

Genta and Emisphere sign licensing agreement for oral gallium compound

Enrollment completed in phase II solid tumor study of CA4P with chemotherapy

Grip strength measurements improve in BioAstin tendonitis study

Noxxon and Pfizer form Spiegelmer product alliance

Pharming to acquire DNage

Reata advances RTA-402 into clinical testing

Paion begins program for next-generation plasminogen activators

Mimetogen completes Series A financing, new licensing agreement

Bioaccelerate Holdings to change name, spin off subsidiaries

Positive opinion handed down in Europe for Ganfort

Exenatide LAR studied for type 2 diabetes in new study

Opposing trends in Oncophage renal cancer phase III trial

CHMP recommends against approval of Zelnorm for IBS-C in Europe

Phase II data for ALGRX-4975 in hernia repair at odds with other phase II results

New dosages of Risperdal M-TAB now available

Rectogesic completes E.U. mutual recognition procedure

Novel calcium-sensing receptor antagonist promotes PTH release in vivo

Affibody molecules -- a tool for preclinical drug profiling

Inhibitors of 11beta-HSD1: candidates for the treatment of obesity, diabetes and metabolic syndrome

Lyrica receives European approval for GAD

Aranesp approved for every-three-week dosing

New treatment options for cancer covered in recent patents

Cubist responds to approvable letter for Cubicin

Data on new chemokine CXC receptor antagonists reported at ACS meeting

Preclinical data on the antidiabetic compound SYR-322 presented

A novel target to improve memory: ghrelin

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...